# Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

> **NCT05927857** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 45 (estimated)

## Conditions studied

- Metastatic Gastric Adenocarcinoma
- Second Line
- Chemotherapy

## Interventions

- **DRUG:** nal-IRI /Experimental
- **DRUG:** Ramucirumab /Experimental
- **DRUG:** Trifluridine/Tipiracil /Experimental

## Key facts

- **NCT ID:** NCT05927857
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05927857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05927857, "Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05927857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*